MILLENNIUM PHARMACEUTICALS REPORTS RESULTS OF MLN1202 TRIAL

A A

Millennium Pharmaceuticals has announced positive top-line results from the company's randomized, double-blinded, placebo-controlled Phase II clinical trial of MLN1202, a novel humanized monoclonal antibody that specifically targets the CCR2 chemokine receptor, in patients at high risk for atherosclerotic cardiovascular disease.

Preliminary analysis showed that MLN1202 was well tolerated and fully met its primary endpoint of a significant reduction in C-reactive protein levels, an inflammatory biomarker associated with atherosclerosis, for months after a single dose of MLN1202.